| Primary information |
|---|
| ID | antitb_1221, |
| Name | 23603838 |
| N-Terminal modification | PK34 |
| C-Terminal Modification | PRVIETKVHGREVTGLARNVSEENVDRLAKRWIK |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 34 |
| Source | L |
| Origin | Cationic |
| Species | Synthetic |
| Strain | Searched and selected from mycobacteriophage genome sequences |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv strain (ATCC 27294 |
| Cell Line | MIC = 50 μg/ml |
| Inhibition Concentration | Both |
| Sequence | 2013 |
| Cytotoxicity | Murine macrophage-like J774A.1 |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | Four-week-old female BALB/c mice |
| Mechanism of Action | Dose of 20 mg (5×10−6 mol)/kg BW/d, PK34 had co |
| Target | Inhibits the proinflammatory factor (IFN-γ, TNF-α, MCP-1, IL-6, IL-10, IL-12) production of macrophage cells induced by TDM. |
| Combination Therapy | Cell wall disruption |
| Other activities | trehalose-6,6=-dimycolate (TDM) |
| PMID | None |
| Year of Publication | None |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1555, |
| Name | 25613372 |
| N-Terminal modification | Pk34 |
| C-Terminal Modification | PRVIETKVHGREVTGLARNVSEENVDRLAKRWIK |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 34 |
| Source | L |
| Origin | Cationic |
| Species | Mycobacteriophage derived |
| Strain | Derived from mycobacteriophage |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | IC50= 50 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | Macrophage like J774A.1 cell line |
| Immune Responce | BALB/C mice |
| Mechanism of Action | 20mg/Kg |
| Target | Increase production of cytokine like IFN-γ,TNF-α,IL-12,MCp-1, IL-10, IL-6 |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Bactericidal against E.coli, pseudomonas, S.aureus, Bacillus subtilis |
Tertiary Structure
(Technique) | Not Predicted), |